logo
Site Network

Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Regional Cancer Centre - Thiruvananthapuram

Verified
+914712442541
webmaster@rcctvm.gov.in
Source: Site record.
https://www.rcctvm.gov.in

Basic Information

Site Overview

Source: Human-provided.

Regional Cancer Centre (RCC), Thiruvananthapuram is a premier government-supported comprehensive cancer centre providing medical, surgical, radiation and paediatric oncology services, along with advanced diagnostic and research facilities. It has a large patient base and established experience in multicentre clinical trials and cancer research.

Business Status

Source: Human-provided. OPEN

Business Category

Source: Human-provided. Cancer treatment center

Business Subcategory

Source: Human-provided. Cancer treatment center
Source: Human-provided. Specialized hospital
Source: Trial-derived.
27Total Trials
Source: Trial-derived.
7Recruiting Trials
Source: Trial-derived.
18Active Trials
Source: Trial-derived.
6Completed Trials
Source: Trial-derived.
28Unique Conditions
Source: Trial-derived.
36Unique Sponsors

Affiliations

Conditions

Source: Trial-derived. Breast Neoplasms (3)Source: Trial-derived. Carcinoma, Non-Small-Cell Lung (3)Source: Trial-derived. Neoplasm Metastasis (3)Source: Trial-derived. Breast Cancer (2)Source: Trial-derived. Head and Neck Cancer (2)Source: Trial-derived. Multiple Myeloma (2)Source: Trial-derived. Acute Myeloid Leukemia (1)Source: Trial-derived. Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (1)

Sponsors

Source: Trial-derived. Eli Lilly and Company (8)Source: Trial-derived. Bayer (2)Source: Trial-derived. Karyopharm Therapeutics Inc (2)Source: Trial-derived. Loxo Oncology, Inc. (2)Source: Trial-derived. National Cancer Centre, Singapore (2)Source: Trial-derived. AbbVie (1)Source: Trial-derived. AIMS Institute (1)Source: Trial-derived. AstraZeneca (1)

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Telehealth study visits

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Electrocardiography (lead count not stated)

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Histology / pathology

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Bone marrow biopsy
Source: AI-inferred. Intensity-modulated radiation therapy
Source: AI-inferred. Tumour tissue biopsy (guidance not stated)

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot
Source: Google. Wheelchair accessible restroom

Amenities

Amenities Available

Source: Google. Restroom

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. ESR1 mutation testing
Source: AI-inferred. RET fusion testing
Source: AI-inferred. Serum and urine protein electrophoresis / immunofixation
Source: AI-inferred. Tumour response imaging